Nexien BioPharma (NXEN) Stock Statistics & Valuation Metrics
Total Valuation
Nexien BioPharma has a market cap or net worth of $7,077.00. The enterprise value is $374.17B.
- Market Cap
- $7,077.00
- Enterprise Value
- $374.17B
Share Statistics
Nexien BioPharma has 70,772,194 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 70,772,194
- Owned by Insiders
- ―
- Owned by Institutions
- 0.12%
Financial Efficiency
Nexien BioPharma’s return on equity (ROE) is 0.66 and return on invested capital (ROIC) is 318.40%.
- Return on Equity (ROE)
- 0.66
- Return on Assets (ROA)
- -57.14
- Return on Invested Capital (ROIC)
- 318.40%
- Return on Capital Employed (ROCE)
- 0.43
- Revenue Per Employee
- 0
- Profits Per Employee
- -23.90K
- Employee Count
- 10
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Nexien BioPharma is -0.03. Nexien BioPharma’s PEG ratio is -0.00.
- PE Ratio
- -0.03
- PS Ratio
- 0.00
- PB Ratio
- -0.02
- Price to FCF
- -0.11
- Price to Operating Cash Flow
- -0.10
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Nexien BioPharma had revenue of 0 and earned -239.00K in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -156.00K
- Pretax Income
- -239.00K
- Net Income
- -239.00K
- EBITDA
- -337
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -61.78K and capital expenditures 1, giving a free cash flow of -61.78K billion.
- Operating Cash Flow
- -61.78K
- Free Cash Flow
- -61.78K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Nexien BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -909.48%
- Earnings Yield
- -3610.60%
Stock Price Statistics
- Beta
- -2.97
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Nexien BioPharma as a current ratio of 0.01, with Debt / Equity ratio of -86.44%
- Current Ratio
- 0.01
- Quick Ratio
- 0.01
- Debt to Market Cap
- 0.27
- Net Debt to EBITDA
- -914.16
- Interest Coverage Ratio
- -1.87
Taxes
In the past 12 months, Nexien BioPharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Nexien BioPharma EV to EBITDA ratio is -935.16, with an EV/FCF ratio of -4.90.
- EV to Sales
- 0.00
- EV to EBITDA
- -935.16
- EV to Free Cash Flow
- -4.90
- EV to Operating Cash Flow
- -4.90
Balance Sheet
Nexien BioPharma has $8,285.00 in cash and marketable securities with $375.38K in debt, giving a net cash position of -$367.09K billion.
- Cash & Marketable Securities
- $8,285.00
- Total Debt
- $375.38K
- Net Cash
- -$367.09K
- Net Cash Per Share
- -$0.01
- Tangible Book Value Per Share
- -$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Nexien BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
